

Swayamjeet Satapathy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152340/publications.pdf>

Version: 2024-02-01

25
papers

409
citations

840776

11
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

446
citing authors

#	ARTICLE	IF	CITATIONS
1	â€˜Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and metaâ€˜analysisâ€™™. Clinical Endocrinology, 2019, 91, 718-727.	2.4	71
2	Diagnostic Accuracy of ⁶⁸ Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2021, 216, 599-607.	2.2	50
3	Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancerâ€˜a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 880-890.	3.9	38
4	Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy. Clinical Nuclear Medicine, 2020, 45, 935-942.	1.3	33
5	177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors. Nuclear Medicine Communications, 2019, 40, 1195-1203.	1.1	28
6	177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1754-1764.	6.4	25
7	Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial. Complementary Therapies in Medicine, 2020, 53, 102526.	2.7	23
8	Effect of Tulsi (Ocimum sanctum Linn.) Supplementation on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects. Indian Journal of Clinical Biochemistry, 2017, 32, 357-363.	1.9	19
9	Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clinical Nuclear Medicine, 2020, 45, e393-e399.	1.3	17
10	Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian Journal of Nuclear Medicine, 2020, 35, 299.	0.3	16
11	18F-FDG PET/CT in Tuberculosis. Clinical Nuclear Medicine, 2020, 45, 276-282.	1.3	14
12	Clinical determinants of severe COVID-19 disease â€˜A systematic review and meta-analysis. Journal of Global Infectious Diseases, 2021, 13, 13.	0.5	13
13	Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience. Nuclear Medicine Communications, 2020, 41, 629-635.	1.1	12
14	¹⁷⁷ Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Global Oncology, 2021, 7, 1167-1175.	1.8	10
15	Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy. Clinical Nuclear Medicine, 2022, 47, e466-e467.	1.3	8
16	Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (¹⁷⁷ Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 23-29.	1.0	6
17	Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 2022, 35, 749-760.	0.9	6
18	COVID-19 related multisystem inflammatory syndrome in children (MIS-C): Role of 18F-FDG PET/CT to assess myocardial involvement. Journal of Nuclear Cardiology, 2022, 29, 3546-3547.	2.1	5

#	ARTICLE	IF	CITATIONS
19	Short-course ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?. <i>European Urology</i> , 2021, 80, 390-392.	1.9	5
20	Alpha Before Beta. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, .	1.3	4
21	¹⁸ F-NaF PET uptake characteristics of coronary artery culprit lesions in a cohort of patients of acute coronary syndrome with ST-elevation myocardial infarction and chronic stable angina: A hybrid fluoride PET/CTCA study. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 558-568.	2.1	2
22	Radioactive Iodine as a Single-Modality Treatment in a Tumor Thrombus Arising from Follicular Thyroid Carcinoma. <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 82-83.	0.8	2
23	Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
24	Expression of CXCR4 Receptors in Refractory Atypical Mediastinal Carcinoid. <i>Clinical Nuclear Medicine</i> , 2020, 45, e422-e424.	1.3	0
25	Axillary Lymph Nodal Metastases from Thyroid Carcinoma: Report of 2 Cases with Review of Literature. <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 89-91.	0.8	0